- Home
- AMGN vs TMO Comparison
AMGN vs TMO Comparison
Compare AMGN & TMO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | AMGN | TMO |
|---|---|---|
| Founded | 1980 | 1956 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Industrial Machinery/Components |
| Sector | Health Care | Industrials |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 224.2B | 255.1B |
| IPO Year | 2002 | 1996 |
Fundamental Metrics
Financial Performance| Metric | AMGN | TMO |
|---|---|---|
| Price | $466.83 | $694.66 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 34 | 27 |
| Target Price | $397.32 | ★ $752.12 |
| AVG Volume (30 Days) | ★ 2.3M | 2.3M |
| Earning Date | 11-03-2026 | 10-21-2026 |
| Dividend Yield | ★ 2.19% | 0.27% |
| EPS Growth | ★ 88.23 | 7.32 |
| EPS | 7.71 | ★ 9.10 |
| Revenue | ★ $25,424,000,000.00 | $20,918,000,000.00 |
| Revenue This Year | $6.04 | $7.74 |
| Revenue Next Year | $3.63 | $5.27 |
| P/E Ratio | ★ $59.87 | $77.69 |
| Revenue Growth | 8.83 | ★ 14.47 |
| 52 Week Low | $292.13 | $435.27 |
| 52 Week High | $468.27 | $711.85 |
Technical Indicators
Market Signals| Indicator | AMGN | TMO |
|---|---|---|
| Relative Strength Index (RSI) | 71.90 | 57.39 |
| Support Level | $338.03 | $587.41 |
| Resistance Level | N/A | $694.33 |
| Average True Range (ATR) | 10.25 | 20.79 |
| MACD | 3.19 | 0.47 |
| Stochastic Oscillator | 84.54 | 66.66 |
Price Performance
Historical ComparisonAbout AMGN Amgen Inc.
Amgen is a leader in biotechnology-based human therapeutics. Flagship drugs include red blood cell boosters Epogen and Aranesp, immune system boosters Neupogen and Neulasta, and Enbrel and Otezla for inflammatory diseases. Amgen introduced its first cancer therapeutic, Vectibix, in 2006 and markets bone-strengthening drugs Prolia/Xgeva (approved 2010) and Evenity (2019). The acquisition of Onyx Pharmaceuticals bolstered the firm's therapeutic oncology portfolio with Kyprolis, which has been further strengthened with the launch of new drugs in blood cancers (Blincyto) and solid tumors (Imdelltra). The 2023 Horizon acquisition brought several rare-disease drugs, including thyroid eye disease drug Tepezza. Amgen also has a growing biosimilar portfolio.
About TMO Thermo Fisher Scientific Inc
Thermo Fisher Scientific sells scientific instruments and laboratory equipment, diagnostics consumables, and life science reagents. The firm operates through four segments as of year-end 2025 (revenue figures include some cross-segment revenue): analytical technologies (17% of sales); specialty diagnostic products (11%); life science solutions (23%); and lab products and services, which includes CRO services (the remainder).